<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180603039966N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-03</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>New technique in intradiscal injection</public_title>
      <acronym></acronym>
      <scientific_title>Fluoroscopy- guided intradiscal Radiopaque Gellified Ethanol injection using the anteroposterior view in comparison to oblique view – A Randomized Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73956</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants were randomized to treatment groups using a blocked randomization scheme with block sizes of 4, this means that participants were divided into blocks of four, and then each participant within a block was randomly assigned to one of the treatment groups. In this design, patients are randomly divided into 18 groups of four. Then, in each block that includes 4 patients, each injection technique is assigned equally among these four patients. In this way, each injection technique in each block is equally given to four subjects, Blinding description: In this study, the person who is recording the time of the procedure and the exposure dosage is unaware of the technique used. For the person analyzing the information, the two groups are reported as groups A and B. Group A will be related to the Anterior-Posterior technique and Group B will be related to the Oblique technique.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Intervertebral disc disorders with radiculopathy, lumbar region.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In AP view technique, the entry point at which the needle penetrates, is measured through the use of a ruler feature in the MRI images software. In axial image, the line is drawn from center of the disc, passing the ateral border of superior articular process (SAP), to the surface of the skin, then the distance between the entry point and midline will be measured with the software. In AP technique, the desired injection level has been determined using an AP view with a C-Arm device. The procedure takes place under local anesthesia, with 1% lidocaine administered to numb the area. An 18 G Chiba needle is then inserted into the designated point at a distance of approximately 8-10 cm from midline(in accordance to MRI measurement), with 45 degrees angle, after penetration the needle is advanced into the skin until the tip of the needle ultimately hit against lower vertebrae's SAP. Then the needle will be walked off  over the SAP, through the Kambine’s triangle. As we cautiously advance using stepwise movements until the tip of the needle passes medial border of the SAP in AP view, the C-Arm device will be rotated for a true lateral view to control the depth of the needle, we will advanced the needle until hitting resistance, and penetrated through the disc. The needle will be andvanced until the tip is center of the intervertebral disc. Intervention 2: Control group: In the oblique technique, in order to ascertain precise accuracy throughout this process, every patient's injection site anatomy as well as the needle's trajectory path are determined through guidance provided by C-arm imaging. Once these factors have been meticulously identified, we proceed by squering involved vertebrae, then utilizing an oblique view. Within this viewpoint, we carefully select an appropriate point on the skin for needle insertion before delicately introducing an Chiba 18G needle into target disc. As soon as we reach beyond the medial border of the pedicle in anteroposterior (AP) view, confirmation is sought via lateral view analysis. Upon receiving confirmation through this holistic assessment approach and having successfully located our target within center of the intervertebral disc further advancement ceases accordingly at that particular point of penetration with regards to needle tip placement.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sina Hassannasab</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Arghvan building, Mehrangar 6, Sayad 8</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4917964313</zip>
        <telephone>+98 911 313 3385</telephone>
        <email>sina.hasannasab@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sina Hassannasab</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Arghavan Apt., Mehrnegar 6 St. Sayyad 8 St.</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4917964313</zip>
        <telephone>+98 911 313 3385</telephone>
        <email>sina.hasannasab@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>consent to participate
individuals suffer from grade I and II herniated disc
spinal canal stenosis of less than 30% as determined by clinical examinations and MRI findings
chronic back pain for more than six months
symptomatic disc herniation
radial foot pain on one or both sides
no axial pain
do not have degenerative disc disease
no history of RGE injection in the last six months
no opioid usage
no coagulation disorder
not being pregnant
no history of malignancy
no history of spinal deformities, prior spine surgeries, traumatic injuries causing vertebral fractures, or infections in the vertebrae
lumbar disc herniation in L3 and/or L4
no history of neurological impairments
no history of psychiatric problems</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unexpected allergy to antiseptic agents
Unexpected allergy to local anesthetics
Unexpected allergy to intravenous sedatives</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M51.16</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Intervertebral disc disorders with radiculopathy, lumbar region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In AP view technique, the entry point at which the needle penetrates, is measured through the use of a ruler feature in the MRI images software. In axial image, the line is drawn from center of the disc, passing the ateral border of superior articular process (SAP), to the surface of the skin, then the distance between the entry point and midline will be measured with the software. In AP technique, the desired injection level has been determined using an AP view with a C-Arm device. The procedure takes place under local anesthesia, with 1% lidocaine administered to numb the area. An 18 G Chiba needle is then inserted into the designated point at a distance of approximately 8-10 cm from midline(in accordance to MRI measurement), with 45 degrees angle, after penetration the needle is advanced into the skin until the tip of the needle ultimately hit against lower vertebrae's SAP. Then the needle will be walked off  over the SAP, through the Kambine’s triangle. As we cautiously advance using stepwise movements until the tip of the needle passes medial border of the SAP in AP view, the C-Arm device will be rotated for a true lateral view to control the depth of the needle, we will advanced the needle until hitting resistance, and penetrated through the disc. The needle will be andvanced until the tip is center of the intervertebral disc.</i_keyword>
      <i_keyword>Control group: In the oblique technique, in order to ascertain precise accuracy throughout this process, every patient's injection site anatomy as well as the needle's trajectory path are determined through guidance provided by C-arm imaging. Once these factors have been meticulously identified, we proceed by squering involved vertebrae, then utilizing an oblique view. Within this viewpoint, we carefully select an appropriate point on the skin for needle insertion before delicately introducing an Chiba 18G needle into target disc. As soon as we reach beyond the medial border of the pedicle in anteroposterior (AP) view, confirmation is sought via lateral view analysis. Upon receiving confirmation through this holistic assessment approach and having successfully located our target within center of the intervertebral disc further advancement ceases accordingly at that particular point of penetration with regards to needle tip placement.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Radiation exposure. Timepoint: Is mesured during the application of intervention. Method of measurement: Dose area product (DAP) meters are utilized to evaluate patient dose by employing an ionization chamber positioned on the collimator of the X-ray tube.</prim_outcome>
      <prim_outcome>Procedure duration. Timepoint: The Procedure Time(PT) is carefully measured, beginning when the first fluoroscopic image was taken and ending only when the needle tip accurately reached its intended target point within the nucleus pulposus. Method of measurement: chronometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-11-12</approval_date>
        <contact_name>Shahid-Beheshti Medical University Ethics Committee</contact_name>
        <contact_address>Shahid Chamran Highway - Yemen St. - Arabi St., Shahid Beheshti University of Medical Sciences and Healthcare Services - building number two of the university headquarters - 6th floor tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
